Rewriting the Autoimmune
Treatment Playbook

Learn More

01

Rewriting the Autoimmune Treatment Playbook

About Us

Alumis Inc. is a precision medicines company with the mission to transform the lives of patients with autoimmune diseases. Our experienced leadership team brings a proven track record in precision drug development of groundbreaking therapies.

Even with treatment innovations of the last two decades, many patients with immunologic conditions continue to suffer.

With a unique precision analytics platform and an unwavering commitment to advancing our understanding of immunologic diseases, Alumis Inc. will rewrite the autoimmune treatment playbook by developing the right medicine for each patient.

Meet the Team

02

Leadership Team

Rewriting the Autoimmune Treatment Playbook

Martin Babler

President and CEO, Chairman of the Board

Mark Bradley

Chief Development Officer

David Zhang, Ph.D.

Senior Vice President, Chief Information Officer

Travis Remarchuk, Ph.D.

Executive Director, CMC

Jeff Douglas

Vice President, Clinical Operations

David Goldstein, Ph.D.

Chief Scientific Officer and Head of CMC

Roy Hardiman, J.D.

Chief Business and Legal Officer

Ken Brameld, Ph.D.

Alumis Fellow and Head of Research

Claire Langrish, Ph.D.

SVP Immunology and Biology

Tori Lovell

HR Business Partner

Mike Taylor, Ph.D.

Vice President of Toxicology

David Alonzo, Ph.D.

Sr. Director of CMC

Carmen Munoz

Sr. Administrative Assistant / Project Coordinator

Shereen McIntyre

Executive Director of Data Management

Milly Kitty Toor

Senior Director, Commercial Development

Regan Burns

Associate Director of Clinical Operations

Derrick Richardson

Vice President of Program Management

Fareha Iqbal, M.D.

Associate Medical Director of Clinical Development

Dennis Leventis

Associate Director of IT

Sara Klein

General Counsel and Secretary

Kareem Graham, Ph.D.

Director, Biology

Kolbot By

Senior Vice President of Technical Operations

Ryan Yu

Scientist, Biology

Joyce Kwan

Senior Scientist, Biology

Mera Tilley, Ph.D.

Vice President in Genetics and Precision Immunology

Jennifer Cortes

Sr. Executive Assistant

Natalie Loewenstein

Sr. Research Associate, Biology

Joshua Hoffman

Director, Statistical Genetics

Adrienne Robinson

Sr. Director, Vendor Outsourcing & Vendor Partnerships

Linda Chan-Kim

Director, Development Systems & Business Informatics

Dean Dragoli

Executive Director, Medicinal Chemistry

Board of Directors

Martin Babler

President and CEO, Chairman of the Board

Julian Baker

Managing Member of Baker Brothers Investments

Alan Colowick

Managing Director AyurMaya, an affiliate of Matrix Capital Management

Jim Tananbaum, M.D.

Founder and CEO, Foresite Capital

Zhengbin (Bing) Yao, Ph.D.

CEO, ArriVent Biopharma

03

Rewriting the Autoimmune Treatment Playbook

Why it Matters

Our goal is to eliminate suffering and fundamentally change the outcomes for patients living with  autoimmune diseases.

The broad impact of autoimmune disease in the U.S. requires a new approach and better options. We aim to do this by leveraging our precision analytics platform, powered by Foresite Labs, which comprises high-quality curated genetic, clinical and health records data. We then combine that information with the unmatched knowledge and expertise of our team, in order to inform which targets, pathways, indications, and patient subsets we pursue.

 

#3
Cause of chronic illness
25M
People in the US alone diagnosed with autoimmune disease
20-40
Average age at onset of 5 most common autoimmune diseases

04

Rewriting the Autoimmune Treatment Playbook

Our Approach

 

We aim to get the right medicine to each patient. Our leaders are experienced drug developers who are boldly committed to creating new knowledge and then following the science to take on the challenge of precision immunology.

We believe that our unique analytics platform with high-quality curated genetic, clinical and health records data will inform us on smarter targets, pathways, indications, and patient subsets to pursue.

05

Our Pipeline

We are building a pipeline of therapeutics based on genetically validated targets for application in the treatment of multiple autoimmune disease indications.

 


Our pipeline is led by ESK-001, a potentially best-in-class TYK2 inhibitor currently in clinical development for psoriasis with multiple other indications soon to follow. TYK2 is a gene that encodes a member of the tyrosine kinase and, more specifically, the well-known Janus kinases (JAKs) protein families. It is a central node in the signaling pathways of cytokines known as key mediators of inflammation and autoimmune diseases. This highly validated target has the potential to effectively treat multiple autoimmune indications beyond psoriasis.

Beyond TYK2, we have several discovery assets comprised of rigorously validated targets for the potential treatment of autoimmune indications.

06

Authenticity is Our Core

Join Us

We are scientists, drug hunters and company builders – we’ve done this before – and we know that success comes from hard work, grit and staying true to our founding vision. We can’t create real, meaningful therapies for patients without being real with ourselves.

We invite you to join us on this epic journey. Find out how.

Join Us

07

What We’ve Been Up To

Latest News

04/06/22

Alumis Expands Industry-Leading Leadership Team With Appointments of Sara Klein as General Counsel and Secretary and John R. Schroer as Chief Financial Officer

Read More
01/06/22

Esker Therapeutics Announces Name Change to Alumis and Completion of $200 Million Series B

Read More
08/19/21

Alumis Inc. (formerly known as Esker) Appoints Jeff Douglas as Vice President of Clinical Operations

Read More
Top